Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials
Jaleh Fallah(United States Food and Drug Administration), Harpreet Singh(United States Food and Drug Administration), Anup Amatya(Center for Drug Evaluation and Research), Amna Ibrahim(Beni-Suef University), Michael H. Brave(United States Food and Drug Administration), James Xu(United States Food and Drug Administration), Daniel L. Suzman(United States Food and Drug Administration), Shenghui Tang(United States Food and Drug Administration), Bellinda L. King‐Kallimanis(LUNGevity Foundation), Richard Pazdur(United States Food and Drug Administration), Paul G. Kluetz(United States Food and Drug Administration), Laleh Amiri‐Kordestani(United States Food and Drug Administration), Jamie R. Brewer(Center for Democracy in the Americas), Marc R. Theoret(United States Food and Drug Administration), Mitchell S. Anscher, Sundeep Agrawal(Center for Drug Evaluation and Research), Kirsten B. Goldberg(United States Food and Drug Administration), Vishal Bhatnagar(Yashoda Hospital), Elaine Chang(Center for Drug Evaluation and Research), Chana Weinstock(United States Food and Drug Administration), Yutao Gong(Center for Drug Evaluation and Research), Dow-Chung Chi(Center for Drug Evaluation and Research), Julia A. Beaver(Center for Drug Evaluation and Research), Lijun Zhang(Dalian Medical University), M Hadadi(Center for Drug Evaluation and Research)
Cited by 15
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k